PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Exclusion Criteria

• •Here is the translated text:
• •1. Subjects who have previously used any PI3K inhibitors;
• •2. Clinical conditions of dysphagia, malabsorption, or other chronic gastrointestinal diseases that may interfere with compliance and/or absorption of the study drug;
• •3. Unable to discontinue medications that may prolong the QT interval (such as antiarrhythmic drugs) during the study period;
• •4. Active viral, bacterial, or fungal infections requiring treatment (e.g., pneumonia);
• •5. HBV or HCV infection (defined as HBsAg and/or HBcAb positive with HBV DNA copy number ≥ upper limit of normal reference value) or acute or chronic active hepatitis C (HCV) antibody positive;
• •6. History of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation, or history of allogeneic bone marrow or hematopoietic stem cell transplantation;
• •7. Received autologous hematopoietic stem cell transplantation within 90 days before the first dose of study treatment;
• •8. Presence of severe or uncontrolled cardiovascular disease;
• •9. Presence of severe concomitant diseases that endanger patient safety or are deemed by the investigator to affect the completion of the study (e.g., uncontrolled hypertension, diabetes, thyroid disease);
• •10. Pregnant or breastfeeding female patients, or baseline pregnancy test positive for women of childbearing potential;
• •11. Diagnosed or treated for other malignancies within the past 5 years;
• •12. Any other condition that the investigator deems unsuitable for participation in the study.